Company intelligence / Profile preview
Orum Therapeutics
Lexington, Massachusetts, United Statesorumrx.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
Orum is advancing its GSPT1-directed TPD² programs with promising preclinical data supporting selective degradation of intracellular targets. The company aims to improve therapeutic windows by enhancing potency and tolerability through cell-specific delivery.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Targeted Protein Degraders conjugated with antibodies (Antibody Drug Conjugates - ADCs)Novel protein degrader payloads designed to selectively degrade intracellular proteins
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Orum Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orum Therapeutics.